Contineum concludes enrolment in Phase II multiple sclerosis therapy trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2025
0mins
Should l Buy ?
Source: Yahoo Finance
Phase II Trial Completion: Contineum Therapeutics has completed the enrolment of 168 subjects in its Phase II trial, PIPE-307 VISTA, aimed at treating relapsing-remitting multiple sclerosis (RRMS), with results expected by the third quarter of this year.
Future Developments: The company is also developing another treatment, PIPE-791, for various conditions including idiopathic pulmonary fibrosis and chronic pain, under a partnership with Janssen Pharmaceutica NV.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
